For GHK-Cu, animal wound and hair-follicle findings should be read as preclinical evidence unless matched by human clinical data [6], [16]
Evolview v3: a webserver for visualization, annotation, and management of phylogenetic trees
3% GHK-Cu (Copper Tripeptide-1) Biomimetic peptide to support skin firmness, reduce fine lines, and stimulate collagen production 5% Niacinamide (Vitamin B3) Supports skin barrier function and helps improve skin texture Ubiquinone (CoQ10) Lipid-soluble antioxidant to neutralise free radical activity and support skin renewal Sodium Hyaluronate Low-molecular-weight humectant for multi-depth hydration of skin Panthenol (Pro-Vitamin B5) Supports skin barrier function and moisture retention Glycerin Draws moisture into the skin for lasting comfort Tocopherol (Vitamin E) Antioxidant support for healthier-looking skin Allantoin Soothing active to support skin comfort and smoothness Ingredients: Aqua, Niacinamide, Glycerin, Panthenol, Copper Tripeptide-1, Phenoxyethanol, Ethylhexylglycerin, Sodium Hyaluronate, Hydroxyethylcellulose, Allantoin, Tocopherol, Parfum, Ubiquinone, Benzyl Benzoate

Integrating markers of eryptosis (Table 3) into routine clinical monitoring could enable early identification of patients at high risk of progressive anemia or inflammation-driven erythrocyte loss, particularly in non-dialysis-dependent CKD (NDD-CKD) and peritoneal dialysis (PD) patients with residual renal function
The practice comes from observations that continuous peptide use may reduce effectiveness over time and that breaks allow receptor sensitivity to reset